Kestra Medical Technologies (NASDAQ:KMTS) Insider Brian Daniel Webster Sells 8,948 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 8,948 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $22.60, for a total transaction of $202,224.80. Following the sale, the insider owned 540,132 shares of the company’s stock, valued at approximately $12,206,983.20. The trade was a 1.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total transaction of $311,366.64.
• On Thursday, July 30th, Brian Daniel Webster sold 7,857 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.72, for a total transaction of $178,511.04.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total transaction of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total transaction of $314,400.00.

Kestra Medical Technologies Stock Up 5.1%

KMTS stock opened at $23.99 on Tuesday. Kestra Medical Technologies, Ltd. has a one year low of $14.10 and a one year high of $30.00. The firm has a market cap of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The firm’s 50 day moving average price is $22.62 and its 200-day moving average price is $22.48. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The business had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. On average, equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Key Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
• Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.

Hedge Funds Weigh In On Kestra Medical Technologies

Institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC purchased a new stake in shares of Kestra Medical Technologies during the fourth quarter worth $31,000. Russell Investments Group Ltd. raised its stake in shares of Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after acquiring an additional 474 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the period. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies during the 4th quarter worth $72,000. Finally, Brown Brothers Harriman & Co. grew its stake in Kestra Medical Technologies by 26.8% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.

Analyst Ratings Changes

KMTS has been the subject of a number of research analyst reports. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. The Goldman Sachs Group reduced their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. Finally, Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies has a consensus rating of “Hold” and an average price target of $27.83.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.